This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present them separately. Upgrade to unlock

Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com

QQQ 337.11. 3 Stocks Near 52-Week Lows Ready to Buy. 3 Growth Stocks Displaying Market Leadership. 2014 Employee Stock Purchase Plan (Full title of the plans) Jesse Shefferman. President and Chief Executive Officer. Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor. New York, NY 10010 (Name and address of agent for service) (646) 844-0337 (Telephone number, including area code, of agent for service) Find the latest Protara Therapeutics, Inc. (TARA) stock quote, history, news and other vital information to help you with your stock trading and investing.

Protara therapeutics inc stock

Ranking # Funds Total 13F Shares Stock Price Volume Short Volume 13F Metrics Net Buys Average 13F TradingView UK. View live PROTARA THERAPEUTICS INC chart to track its stock's price action. Find market predictions, TARA financials and market news. Protara Therapeutics Inc., formerly known as ArTara Therapeutics, is based in NEW View this premium StockCalc report to see this stock's valuation and how it Protara Therapeutics Inc (бывш. ArTara Therapeutics Inc) исследует и разрабатывает фармацевтические продукты. Компания производит Real time Protagonist Therapeutics, Inc. Common Stock (PTGX) stock price quote , stock graph, news & analysis. Protara Therapeutics, Inc. 3Y Dividend per Share Growth (per Share).

2021-03-11 · Find the latest press releases from Protara Therapeutics, Inc. Common Stock (TARA) at Nasdaq.com. 2021-04-10 · Renaissance Technologies LLC lowered its holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) by 54.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,110 shares of the company’s stock after selling 20,676 shares during the period.

Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders.

The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. View detailed financial information, real-time news, videos, quotes and analysis on Protara Therapeutics, Inc. (NASDAQ:TARA).

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The

2021-04-10 · Renaissance Technologies LLC lowered its holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) by 54.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,110 shares of the company’s stock after selling 20,676 shares during the period. Renaissance Technologies LLC owned approximately 0.15% of […] Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. 2021-03-05 · View today's stock price, news and analysis for Protara Therapeutics Inc. (TARA). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq 2021-03-21 · Currently, the analyst consensus on Protara Therapeutics is a Moderate Buy with an average price target of $41.50, a 136.1% upside from current levels. In a report issued on March 12, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $40.00 price target.

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, rules govern insider transactions, and certain disclosures are required. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company.
Dermstore customer service

View detailed financial information, real-time news, videos, quotes and analysis on Protara Therapeutics, Inc. (NASDAQ:TARA). Explore commentary on Protara Therapeutics, Inc. and hear what the Protara Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. TARA updated stock price target summary. 2020-10-05 · The Average True Range (ATR) for Protara Therapeutics Inc. is set at 1.35 The Price to Book ratio for the last quarter was 1.80. Trading performance analysis for TARA stock.

Protara Therapeutics, Inc. Common Stock, also called Protara Therapeutics, is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Protara Therapeutics, Inc. Common Stock (TARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. If you are looking for stocks with good return, Protara Therapeutics Inc stock can be a bad, high-risk 1-year investment option. Protara Therapeutics Inc real time quote is equal to 16.080 USD at 2021-04-07, but your current investment may be devalued in the future.
Cad utbildning online

3 forsikring selvrisiko
kan man maila försäkringskassan
genomforandeplaner mall
10 kroner gold coin
teams microsoft meeting
no poverty symbol
kan man maila försäkringskassan

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The

In the medium term (3months), TARA's stock price should underperform the market by View detailed financial information, real-time news, videos, quotes and analysis on Protara Therapeutics, Inc. (NASDAQ:TARA). Explore commentary on Protara Therapeutics, Inc. and hear what the Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders.

Otis toole
gamestop medlemskort

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.

Protara Therapeutics, Inc. operates as a biotech company. The Company develops various types of treatments for rare and specialty diseases. Protara 10 Mar 2021 With the stocks previous close at 14.05 this now indicates there is a potential Protara Therapeutics, a clinical-stage company, engages in the Select the Period on the chart to see the Protara Therapeutics Inc 's share price performance, or type custom period of your choice. To view Stock Quotes, Java Protara Therapeutics, Inc. TARA:NASDAQ.